The central role of pathology labs in breast cancer precision oncology: a call for action

被引：1

作者：

Pruneri, Giancarlo ^{[1
,2
]}

Lorenzini, Daniele ^{[1
]}

Mastropasqua, Mauro G. ^{[3
]}

Perrone, Giuseppe ^{[4
]}

Rizzo, Antonio ^{[5
]}

Santini, Donatella ^{[6
]}

Volpi, Chiara C. ^{[1
]}

Cinieri, Saverio ^{[7
,8
]}

Zambelli, Alberto ^{[9
]}

Sapino, Anna ^{[10
]}

Castellano, Isabella

机构：

[1] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy

[2] Univ Milan, Sch Med, Milan, Italy

[3] Univ Bari Aldo Moro, Sch Med, Dept Emergency & Organs Transplantat, Sect Anat Pathol, Bari, Italy

[4] Campus Biomed Univ, Res Unit Pathol, Rome, Italy

[5] Humanitas Ist Clin Catanese, UO Anat Patolog, Catania, Italy

[6] Azienda Osped Univ Bologna, Pathol Unit, IRCCS, Bologna, Italy

[7] ASL Brindisi, Senatore Antonio Perrino Hosp, Med Oncol Div, Brindisi, Italy

[8] ASL Brindisi, Senatore Antonio Perrino Hosp, Breast Unit, Brindisi, Italy

[9] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Milan, Italy

[10] FPO IRCCS Candiolo, Candiolo Canc Inst, Candiolo, Italy

来源：

NPJ BREAST CANCER | 2023年 / 9卷 / 01期

关键词：

DISTANT RECURRENCE; PREDICTOR; SIGNATURE; RISK; DECISIONS; THERAPY;

D O I：

10.1038/s41523-023-00506-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multigenic tests represent an essential tool for the selection of adjuvant therapy in estrogen-positive/HER2-negative (ER + /HER2-) early breast cancer (BC). The workflow of these tests, either if they are externalized or carried out in-house, generates a workload for the pathology laboratories, that is often underestimated and may affect timely therapy initiation. Here, we describe the evolving role of pathology laboratories in using multigenic tests and, more in general, in providing adequate tissue for molecular analyses. Moreover, we propose a "reflex testing" model, in which pathologists, based on pre-specified and shared criteria, are expected to action multigene testing independently of multidisciplinary team discussion in ER + /HER2- BC patients, in order to optimize turnaround time and proper therapy intervention.

引用

页数：4

共 23 条

[1] Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update [J].

Andre, Fabrice ;

Ismaila, Nofisat ;

Allison, Kimberly H. ;

Barlow, William E. ;

Collyar, Deborah E. ;

Damodaran, Senthil ;

Henry, N. Lynn ;

Jhaveri, Komal ;

Kalinsky, Kevin ;

Kuderer, Nicole M. ;

Litvak, Anya ;

Mayer, Erica L. ;

Pusztai, Lajos ;

Raab, Rachel ;

Wolff, Antonio C. ;

Stearns, Vered .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) :1816-+

[2] Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline [J].

Blanchette, Phillip ;

Sivajohanathan, Duvaraga ;

Bartlett, John ;

Eisen, Andrea ;

Feilotter, Harriet ;

Pezo, Rossanna ;

Turashvili, Gulisa ;

Williams, Phillip .

CURRENT ONCOLOGY, 2022, 29 (04) :2599-2615

[3] Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study [J].

Buus, Richard ;

Sestak, Ivana ;

Kronenwett, Ralf ;

Ferree, Sean ;

Schnabel, Catherine A. ;

Baehner, Frederick L. ;

Mallon, Elizabeth A. ;

Cuzick, Jack ;

Dowsett, Mitch .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (02) :126-+

[4] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Cardoso, F. ;

Kyriakides, S. ;

Ohno, S. ;

Penault-Llorca, F. ;

Poortmans, P. ;

Rubio, I. T. ;

Zackrisson, S. ;

Senkus, E. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220

[5] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer [J].

Cardoso, F. ;

van't Veer, L. J. ;

Bogaerts, J. ;

Slaets, L. ;

Viale, G. ;

Delaloge, S. ;

Pierga, J. -Y. ;

Brain, E. ;

Causeret, S. ;

DeLorenzi, M. ;

Glas, A. M. ;

Golfinopoulos, V. ;

Goulioti, T. ;

Knox, S. ;

Matos, E. ;

Meulemans, B. ;

Neijenhuis, P. A. ;

Nitz, U. ;

Passalacqua, R. ;

Ravdin, P. ;

Rubio, I. T. ;

Saghatchian, M. ;

Smilde, T. J. ;

Sotiriou, C. ;

Stork, L. ;

Straehle, C. ;

Thomas, G. ;

Thompson, A. M. ;

van der Hoeven, J. M. ;

Vuylsteke, P. ;

Bernards, R. ;

Tryfonidis, K. ;

Rutgers, E. ;

Piccart, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :717-729

[6] Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 [J].

Ferlay, J. ;

Colombet, M. ;

Soerjomataram, I. ;

Dyba, T. ;

Randi, G. ;

Bettio, M. ;

Gavin, A. ;

Visser, O. ;

Bray, F. .

EUROPEAN JOURNAL OF CANCER, 2018, 103 :356-387

[7] A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors [J].

Filipits, Martin ;

Rudas, Margaretha ;

Jakesz, Raimund ;

Dubsky, Peter ;

Fitzal, Florian ;

Singer, Christian F. ;

Dietze, Otto ;

Greil, Richard ;

Jelen, Andrea ;

Sevelda, Paul ;

Freibauer, Christa ;

Mueller, Volkmar ;

Jaenicke, Fritz ;

Schmidt, Marcus ;

Koelbl, Heinz ;

Rody, Achim ;

Kaufmann, Manfred ;

Schroth, Werner ;

Brauch, Hiltrud ;

Schwab, Matthias ;

Fritz, Peter ;

Weber, Karsten E. ;

Feder, Inke S. ;

Hennig, Guido ;

Kronenwett, Ralf ;

Gehrmann, Mathias ;

Gnant, Michael .

CLINICAL CANCER RESEARCH, 2011, 17 (18) :6012-6020

[8]

gazzettaufficiale.it, ITALIAN ESSENTIAL LE

[9] Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone [J].

Gnant, M. ;

Filipits, M. ;

Greil, R. ;

Stoeger, H. ;

Rudas, M. ;

Bago-Horvath, Z. ;

Mlineritsch, B. ;

Kwasny, W. ;

Knauer, M. ;

Singer, C. ;

Jakesz, R. ;

Dubsky, P. ;

Fitzal, F. ;

Bartsch, R. ;

Steger, G. ;

Balic, M. ;

Ressler, S. ;

Cowens, J. W. ;

Storhoff, J. ;

Ferree, S. ;

Schaper, C. ;

Liu, S. ;

Fesl, C. ;

Nielsen, T. O. .

ANNALS OF ONCOLOGY, 2014, 25 (02) :339-345

[10] Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J].

Harris, Lyndsay N. ;

Ismaila, Nofisat ;

McShane, Lisa M. ;

Andre, Fabrice ;

Collyar, Deborah E. ;

Gonzalez-Angulo, Ana M. ;

Hammond, Elizabeth H. ;

Kuderer, Nicole M. ;

Liu, Minetta C. ;

Mennel, Robert G. ;

Van Poznak, Catherine ;

Bast, Robert C. ;

Hayes, Daniel F. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1134-+

← 1 2 3 →